Todos Medical Releases Letter to Shareholders

REHOVOT, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd.. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today released a letter to shareholders:

Dear Shareholders,

Thank you for continuing to support the Company as we embark on this effort to transform into a US-focused blood diagnostics company preparing to embark on a clinical utility study with a view towards obtaining our own CPT code to allow for value-based, consistent reimbursement of an actionable blood test for breast cancer. I was asked by the Company’s Board of Directors to step in as CEO in early January, in large part, due to the prospective acquisition of Provista Diagnostics, which is a US-based blood testing company that has received over $50 million in investment to develop the Videssa^® blood test for breast cancer.

Please find here a link to the Company’s updated corporate presentation: http://investor.todosmedical.com/static-files/815190c5-2c1f-4e21-9309-dd5aab5802d1 . The Company is staying strategically focused in the area of breast cancer, while continuing to develop our Alzheimer’s diagnostic platform.

Breast Cancer

Over the past several weeks, as we have begun to put the infrastructure in place to re-domicile Todos from Israel to the US, I have been repeatedly asked why a company that owns TM-B2, a breast cancer blood test for the dense breast population (BI-RADS III/IV), would buy a competitor that owns Videssa, a competing breast cancer blood test for the dense breast population. Is it because you don’t believe in TM-B2? To be clear, we unequivocally believe in TM-B2. Our rationale for the business combination is as follows:

1. Videssa has been prospectively tested in over 1,100 subjects, vs. over 400 subjects for TM-B2;
2. As Videssa has significantly more prospective clinical validation data, it has achieved a level of clinical validation that allows it to progress to a clinical utility (reimbursement) study;
3. Videssa has shown very strong negative predictive value (NPV) for breast cancer, but poor positive predictive value (PPV), whereas TM-B2 has shown strong NPV and PPV;
4. We have the opportunity to dramatically accelerate the acquisition of data for TM-B2 by ‘piggybacking’ its development onto the clinical utility study for Provista, i.e. we will collect data for both Videssa and TM-B2 during Videssa’s clinical utility study:
   • This will have the benefit of true ‘head to head’ data comparing Videssa and TM-B2;
   • Due to the extremely low cost of running the TM-B2 assay, the incremental cost to the Videssa clinical utility study is expected to be relatively insignificant;
   • The study is being designed to define the value of NPV in breast cancer for Videssa, and would have the upside potential of demonstrating the value of TM-B2
   • The data obtained could potentially support the value of PPV in breast cancer for TM-B2, but at a minimum will provide us with significant analytical and clinical validation data for TM-B2;
5. The market opportunity for a blood test that can triage subjects who have dense breast is so large that regardless of which technology is ultimately the best, Todos shareholders stand to benefit substantially from any positive clinical results;
6. The underlying Todos Total Biochemical Infrared Analysis (TBIA) platform can be leveraged by virtue of the data collected in the Videssa clinical utility study to create additional exploratory and proof of concept data for other cancers, and potentially other diseases.

Alzheimer’s Disease

Todos is also preparing to receive confirmatory data from the second half of an ongoing clinical trial of the Alzheimer’s blood diagnostic LymPro Test through our joint venture, Breakthrough Diagnostics. The importance of this milestone cannot be overstated by virtue of the initial data that we received that demonstrated a very strong correlation with amyloid PET imaging ( p = 0.000002, r = .849). We strongly believe that Alzheimer’s disease is effectively cancer of post-mitotic brain cells (cells that are physiologically no longer able to complete the cell division process), and this upcoming data will provide further evidence of the immune system’s importance in Alzheimer’s disease. Recent data published in the Journal of Experimental Medicine hypothesize that signaling molecules linked to the immune system immune cells in the brain have the potential to alleviate age-related cognitive decline. We believe this provides further evidence that LymPro is on the right track in terms of understanding the role of the immune system in Alzheimer’s disease. A breakthrough in this area could have significant implications for health systems worldwide, especially identifying a peripheral biomarker that could identify individuals at the earliest stages of disease.

Summary

In light of the significant market opportunity the Company has in the areas of cancer and Alzheimer’s, we believe there is tremendous value to be unlocked from the underlying technologies to which Todos has rights. Going forward, the Company will be focused on bridging the gap to allow the Company to achieve interim milestones on its way to a proposed listing on Nasdaq in the first half of 2020.

I would like to sincerely thank you for your continued support of the Company, and I look forward to providing further updates in the near future.

Warmest Regards,

Gerald Commissiong
CEO

About Todos Medical Ltd.
Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer’s disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test^®, a blood test for diagnosing Alzheimer’s disease. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa^® breast cancer blood test.

For more information, the content of which is not part of this press release, please visit http://www.todosmedical.com

Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Investor and Corporate Contact:
Kim Sutton Golodetz
LHA Investor Relations
Senior Vice President
(212) 838-3777
kgolodetz@lhai.com

Corporate Contact
Daniel Hirsch
Todos Medical
Investor Relations
Email: Dan.h@todosmedical.com
Phone: (347) 699-0029